NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Thursday, February, 6th. The medical equipment provider reported $1.51 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.09 by $0.42. The medical equipment provider earned $221.60 million during the quarter, compared to analysts' expectations of $226.92 million. ABIOMED had a net margin of 29.14% and a return on equity of 19.53%. The firm's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.97 EPS. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for ABIOMED.

ABIOMED updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $846-877 million, compared to the consensus revenue estimate of $885.43 million.

7 brokers have issued 1 year price objectives for ABIOMED's stock. Their forecasts range from $165.00 to $340.00. On average, they anticipate ABIOMED's stock price to reach $248.33 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price. View Analyst Price Targets for ABIOMED.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.

Media coverage about ABMD stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ABIOMED earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for ABIOMED.

ABIOMED saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,020,000 shares, a decrease of 6.9% from the January 15th total of 4,320,000 shares. Based on an average daily volume of 894,000 shares, the days-to-cover ratio is presently 4.5 days. Approximately 9.1% of the shares of the stock are sold short. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX), Cardiovascular Systems (CSII) and Cryolife (CRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Arista Networks (ANET), Align Technology (ALGN), Square (SQ), Netflix (NFLX), bluebird bio (BLUE), Intuitive Surgical (ISRG) and Adobe (ADBE).

ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (6.04%), Sands Capital Management LLC (5.42%), Renaissance Technologies LLC (5.16%), State Street Corp (4.56%), William Blair Investment Management LLC (1.43%) and Credit Suisse AG (1.36%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Amundi Pioneer Asset Management Inc., Victory Capital Management Inc., Victory Capital Management Inc., Villere ST Denis J & Co. LLC, William Blair Investment Management LLC, Bank of New York Mellon Corp and Blair William & Co. IL. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Credit Suisse AG, Jackson Square Partners LLC, Renaissance Technologies LLC, Bessemer Group Inc., Global Thematic Partners LLC, State Street Corp and ArrowMark Colorado Holdings LLC. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $167.22.

ABIOMED has a market capitalization of $7.53 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.